Navigation Links
ARIUS announces first quarter fiscal 2008 financial results

TORONTO, April 11 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the first fiscal quarter of 2008, ended February 29, 2008.

"During the quarter, we continued to focus on advancing our antibody drugs efficiently and rapidly towards human clinical trials. Most significantly, we completed our pre-IND meeting with the US FDA for our lead CD44 Cancer Stem Program," said Dr. David Young, President and CEO of ARIUS. "We also presented new findings from our lead programs, including data from our CD9 Cancer Stem Cell program in collaboration with Dr. John Dick, a pioneer in the cancer stem cell field. Maintaining this momentum, five ARIUS abstracts have been selected for presentation in the upcoming AACR Annual meeting this month, demonstrating the scientific community's ongoing interest in our programs and the high quality of our research."

Program Updates:

CD44 Cancer Stem Cell Program

- Selected to present two CD44-focused posters at AACR the American

Association for Cancer Research (AACR) Annual Meeting held from

April 12-16, 2008 in San Diego, California.

- Held meeting with FDA to discuss plans for the upcoming

IND submission.

- Prepared to file a Phase I IND application and begin human

clinical trials for the CD44 Cancer Stem Cell program in 2008.

Trop-2 Signal Transduction Program

- Completed first toxicology studies.

- Selected to present a Trop-2-focused poster at AACR Annual


- Engaged Laureate Pharma Inc. for cGMP manufacturing of humanized

antibody for Phase 1 clinical supply. A cell line producing the

humanized anti-Trop-2 antibody was successfully transferred to


- Pr

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Post Your Comments:
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... 2014  CorMedix Inc. (NYSE MKT: CRMD), a ... products for the prevention and treatment of cardiorenal ... on July 18, 2014 from the NYSE MKT ... CorMedix plan to regain compliance with continued listing ... NYSE-MKT is continuing the Company,s listing and has ...
(Date:7/24/2014)... 1000 balances – 4 steps – One Recommendation: ... and expertly narrows down the mass of product choices ... terminals. , First, select the working environment, then ... instead) and define the accuracy – it’s really that ... the list to models that fit best with the ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 As part ... numerous projects in the MENA region during 2014 with ... a preferred provider agreement with DZS to manage our ... region,” said Global VP of R&D and President of ... developed excellent operational practices with a focus on utilizing ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Medarex, Inc.,(Nasdaq: MEDX ) announced today that it ... Conference at 10:30 a.m. ET on Tuesday, January,8, 2008. ... available in the,Investor Relations section of the Medarex Web ... presentation will be available following the event., About ...
... PARK, N.C., Jan. 3 Chimerix, Inc., a,biotechnology ... Neil Frazer, M.B., Ch.B., FRCA, FFPM has joined ... joining Chimerix, Dr. Frazer served as the Chief ... (previously,Biocure Medical) where he was responsible for the ...
... (Nasdaq: ONXX ) today announced that it ... January 7, at 11:30 a.m.,Pacific Time. Interested parties ... , It is recommended ... order to,register and download any necessary software. For ...
Cached Biology Technology:Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer 2
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... over a 35 year period in which the human ... humans on declining animal numbers. This decline matters because ... crustaceans, slugs and worms bring to our day-to-day lives, ... nutrient cycling, water filtration and human health. , The ... UCL, Stanford and UCSB, focused on the demise of ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... of seven tropical forests around the world has revealed ... less common trees. The landmark study, conducted by 33 ... 27 issue of the journal Science, conclusively demonstrates that ... , Helene Muller-Landau, an assistant professor of ecology in ...
... Mellon University have discovered that our ears use the ... from babbling brooks to wailing babies. These results represent ... is encoded for transmission to the brain, according to ... "News and Views" editorial in the Feb. 23 issue ...
... of Pittsburgh Professor of Anthropology Jeffrey H. Schwartz and ... Jan. 30 in the New Anatomist journal, shows that ... to Schwartz's theory of evolution, originally explained in his ... of Species (John Wiley & Sons, 2000). , In ...
Cached Biology News:Underdogs in the understory: Study suggests nature favors rarer trees 2Carnegie Mellon scientists show brain uses optimal code for sound 2Carnegie Mellon scientists show brain uses optimal code for sound 3Pitt professor's theory of evolution gets boost from cell research 2Pitt professor's theory of evolution gets boost from cell research 3
ID clarifier: platform...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... is used for vertical electrophoresis applications. The cell accommodates ... L of running buffer. It includes the PROTEAN II ... kit, which contains accessories for use with 2.0 mm ... 2 sets of 20 x 20 cm glass plates, ...
Biology Products: